Two New Research Collaborations to Evaluate Potential Retinal Treatments
The National Neurovision Research Institute (NNRI), the clinical support organization of the Foundation Fighting Blindness, recently established research collaborations with two pharmaceutical companies to evaluate potential treatments for retinal degenerative diseases.
Adeona Pharmaceuticals partnership
“We are enthusiastic about this collaboration, because preliminary studies have shown that flupirtine shows promise for slowing vision loss from RP,” says Stephen Rose, Ph.D., chief research officer, Foundation Fighting Blindness. “These studies in animal models will give us a better understanding of the drug’s potential in people with RP.”
Resolvyx Pharmaceuticals partnership
"We are extremely encouraged by the potential for resolvins to treat a number of serious eye diseases, as we have demonstrated that resolvins have a unique ability to naturally inhibit key inflammatory processes, preserve the integrity of eye tissue and promote eye tissue repair," said Per Gjorstrup, M.D., Ph.D., chief medical officer of Resolvyx Pharmaceuticals. "We look forward to working with NNRI to continue to advance our promising ocular compounds to address serious eye diseases for which there are currently no effective treatment options."
For more information about NNRI, visit www.NNRI.info.
- Bone Marrow Stem Cells in Clinical Trial for Retinal Diseases
- GenSight Receives $41.3 Million for Ocular Gene Therapy Development
- Stem Cell Pioneers Creating Retinal Patch to Restore Vision
- XLRS Natural History Study Beginning in Portland, Oregon
- Six Emerging Retinal Therapies Receive $3.1 Million in Foundation Funding